6-Nitroquipazine has higher binding affinity for SERT than other selective serotonin reuptake inhibitors. We have prepared 6-nitroquipazine based rhenium complexes which would lead to the development of potential SPECT imaging agents with 99m Tc for 5-HT transporter.
Introduction
Serotonin transporter (SERT), responsible for the reuptake of serotonin , plays a key role in the regulation of synaptic serotonin levels. 1 Although not fully understood yet, 5-HT is thought to be implicated in many mental disorders including depression, anxiety, schizophrenia, eating disorders and obsessive compulsive disorder. 2 Serotonin transporter sites are the primary targets for common antidepressant drugs such as fluoxetine, sertraline, and paroxetine. In vivo imaging of SERT in living human beings have been pursued either by PET (positron emission tomography) or by SPECT (single photon emission computed tomography) in order to understand the neurological mechanisms underlying those psychiatric disorders. 5 for SPECT, the development of such radiotracers has met with only limited success mostly due to their low signal to noise ratios and poor selectivity. 6 For a routine clinical use, SPECT imaging is preferred to PET technique for its operational convenience and practicality. Both 123 I and 99m Tc are the common radionuclides suitable for SPECT imaging. Attachment of Tc is rather difficult, in synthetic point of view, since it requires a multidentate ligand, connected covalently to the substrate for stable Tccomplexes. 7 Furthermore, the connection of such chelating groups to a substrate inevitably causes the increase of molecular weight and possible conformational changes, which may lead to the reduction of its binding affinity in several orders. The advantages of 123 I are, however, overshadowed by its lesser accessibility, requiring a cyclotron for its generation. It is thus much desirable to develop radiotracers based on more readily available 99m Tc, despite the aforementioned drawbacks.
In this present work, we wish to report synthesis of several 6-nitroquipazine ligands as well as Re-and Tc-complexes as novel potential radiotracers for the imaging of SERT. We chose 6-nitroquipazine for its high binding affinity with SERT. 
Results and Discussion
Adopting the better synthetic procedures developed by one of us, 10 we prepared the key 6-nitroquipazine derivative 10 with hydroxypropyl handle, starting from 3,4-dihydro-2(1H)-quinolinone 1. Deprotonation with 2.0 equiv of LDA at C3 position, followed by quenching with 3-bromopropanol TMS-ether (2) provided the silyl ether 3 in 85% yield. Desilylated alcohol was nitrated to give the dihydroquinolinone 5 in overall yield of 40%. The acetylated product 6 was treated with phosphorus oxychloride and DDQ to give the 2-chloroquipazine 7 in 80% isolated yield. Displacement reaction with 1-piperazinecarboxaldehyde (8) provided 9, which was deacetylated to the alcohol 10. The resulting alcohol was reacted with MsCl in CH 2 Cl 2 to furnish the mesylate 11 in 52% yield (Scheme 1).
The mesylate 11, however, did not undergo substitution reaction with the tetradentate ligand 12. Instead, it underwent intramolecular displacement reaction, leading to the formation of the cyclic ammonium species 13 as shown in Scheme 2, which might be the reason for the low yield in the mesylation step.
Change of the mesylate group on 11 to the bromide or tosylate gave no improvements. Use of the OH group as a nucleophile would be a reasonable alternative. The alcohol 10 was treated with bromoacetyl bromide, before the coupling with 12 to provide the 6-nitroquipazine derivative 14 bearing the ligand for the chelation of Tc or Re.
The ligand 15 was subjected to 99m
Tc loading conditions to produce the 99m Tc-complex 16, which was isolated in pure form by reversed phase HPLC. However, we noticed partial decomposition of the starting ligand and the product 99m Tc-complex at the ester linkage during the incorporation of technetium (Scheme 4).
Due to the instability of the ester linkage, we decided to connect the N 2 S 2 tetradentate ligand directly with the 6-nitroquipazine group via a reductive amination pathway. At this point, we changed the protecting group of the piperazine from formyl to the more stable Boc-group. With the same steps used for the alcohol 10, we prepared the alcohol 19 bearing Boc protecting group in a comparable overall yield (Scheme 5).
Oxidation of the alcohol 19 did not proceed as smoothly as we expected, but still provided sufficient amount of the aldehyde 20 with PDC in 41% yield. Reductive amination of the aldehyde 20 was successfully carried out to give rise to the corresponding precursor 21 in 80% yield (Scheme 6).
Removal of the trityl groups with Hg +2 provided 22 in moderate yield, which was subsequently treated with trichlorooxobis(triphenylphosphine)rhenium 11 to furnish the desired Re-complex 23 in 49% yield. We also prepared the Boc-deprotected Re-complex 24, upon treatment of the complex 23 with 3 N HCl in EtOAc. The Boc-deprotected 99m Tc-complex, however, cannot be prepared with the same sequence used for the Re-complex 24, for its short half-life (t 1/2 = 6 h). Thus, the Boc group on 21 was removed with 3 N HCl to the ligand system 25, prior to Tc loading step (Scheme 7).
In summary, we have prepared two 6-nitroquipazine based Re-complexes for in vitro binding study against SERT and spectroscopic characterizations plus one C, the reaction mixture was warm to rt and stirred for 9 h, which was then quenched by the addition of water. The mixture was extracted with 10 mL of CH 2 Cl 2 three times. The combined organic layer was dried over Na 2 SO 4 and concentrated. The product was isolated by flash column chromatography with EtOAc/ hexanes (2 : 1) 4, 160.8, 148.3, 144.0, 138.2, 135.0, 130.0, 128.7, 124.2, 123.4, 122.6, 65.3, 50.5, 50.0, 45.5, 40.0, 25.6 ; FT-IR (CHCl 3 ) 2924. 5, 2854.4, 1738.0, 1670. 0, 170.8, 163.0, 161.3, 148.9, 145.16, 145.07, 144.5, 138.7, 130.5, 130.04, 130.00, 129.3, 128.45, 128.41, 127.27, 127.19, 124.8, 124.1, 123.2; 67.5, 67.4, 64.7, 58.8, 55.6, 54.5, 51.1, 50.5, 46.1, 40.6, 38.8, 32.8, 31.1, 29.4, 28 .8, FT-IR (CHCl 3 ) 3343. 4, 3057.9, 3008.5, 2960.0, 2925.6, 2855.5, 1738.9 To a mixture of the ligand 15 (23 µg), SnCl 2 (125 µg) and 1 mg of tartaric acid in 0.05 N HCl (10 mL) was added sodium pertechnetate (370-740 MBq) at rt. Upon sonication for 1 min in water bath, the reaction mixture was heated to 100 o C for 1 h, before cooled to rt. The product mixture was analysed and purified by reversed phase HPLC using gradient system of H 2 O and acetonitrile with flow rate of 1 mL/min. The peak with retention time of 16 min showed correct UV profile and radioactivity.
3-(3-Acetoxypropyl)-6-nitro-2-(4-N-Boc-piperazin-1-yl)-quinoline (18).
The mixture of 7 (217 mg, 0.69 mmol) and Boc protected piperazine (17, 194 mg, 1.04 mmol) in 4 mL of anhydrous DMF was stirred for 36 h at 100 o C and then cooled to rt, poured into 50 mL of ice-crushed water. The resulting precipitate was filtered, washed with 50 mL of water and dried under suction for 10 min. The solid was dissolved in 50 mL of CH 2 Cl 2 , dried over Mg 2 SO 4 , concentrated and purified by column chromatography with EtOAc/ hexanes (1 : 3) to give 18 (236 mg) as a yellow solid in 74% yield: 1 H NMR (400 MHz, CDCl 3 ) δ 8.59 (d, J = 2.8 Hz, 1H), 8.31 (dd, J = 9.2, 2.4 Hz, 1H), 7.96 (s, 1H), 7.85 (d, J = 9.2 Hz, 1H), 4.14 (t, J = 6.4 Hz, 2H), 3.65-3.62 (m, 4H), 3.37-3.34 (m, 4H), 2.86 (dd, J = 8.0, 7.6 Hz, 2H), 2.13-2.04 (m, 2H), 2.06 (s, 3H), 1.50 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) δ 171. 4, 163.4, 155.3, 149.1, 144.3, 138.7, 131.0, 129.2, 124.7, 124.1, 123.1, 80.7, 77.3, 64.4, 50.6, 29.5 6, 155.3, 149.0, 144.3, 138.9, 131.7, 129.2, 124.9, 124.0, 122.9, 80.7, 77.4, 62.2, 50.7, 33.6, 30.4, 29.2, 28.4 6, 163.3, 155.3, 149.2, 144.5, 138.8, 130.3, 129.3, 124.7, 124.1, 123.3, 80.7, 77.3, 50.7, 44.1, 29.2, 24.9 ; FT-IR (CHCl 3 ) 2975. 7, 2927.6, 2853.3, 1695.8, 1616 .2 cm 163.4, 155.3, 149.0, 145.2, 145.1, 144.3, 138.5, 131.2, 130.1, 130.0, 129.1, 128.5, 128.4, 127.4, 127.3, 127.1, 124.7, 124.2, 123.1, 80.1, 67.6, 67.5, 59.1, 55.4, 54.7, 50.5, 38.8, 33.0, 31.0, 30.1, 29.3, 28.2; FT-IR (CHCl 3 ) 3348.3, 3058.4, 2973 .6, 2928 .4, 2856 .2, 1682 5, 163.4, 155.3, 149.1, 144.4, 138.4, 131.0, 129.2, 124.7, 124.1, 123.1, 80.8, 59.3, 58.4, 55.2, 50.6, 42.6, 30.5, 30.1, 29.2, 28.0, 25.5, 23.7; FT-IR (CHCl 3 ) 3343.2, 2974 .0, 2929 .4, 2856 .0, 1681 .8 cm overlapped, 1H), 3.96 (ddd, J = 17.6, 14.8, 8.4 Hz, 1H), 4H), 4H), 4H), 2H) , 3,21-3.13 (m, 2H), 2.91-2.84 (m, 3H), 2.33-2.22 (m, 2H), 1.70-1.62 (m, 2H), 1.50 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) δ 187. 2, 163.3, 155.3, 149.3, 144.6, 138.8, 129.7, 129.6, 124.7, 124.1, 123.6, 80.9, 67.5, 65.4, 63.7, 60.6, 50.9, 48.8, 39.8, 30.5, 29.6, 29.3, 25.3 Re-complex 24. To a solution of 23 (32 mg, 0.040 mmol) in 3 mL of EtOAc was added 3 N HCl (1.5 mL) at rt. After stirring for 24 h at rt, the reaction mixture was diluted with EtOAc (10 mL), washed with 1 M NaHCO 3 (2 × 10 mL) and water (10 mL). The organic layer was dried over Na 2 SO 4 2, 163.6, 149.5, 144.5, 138.8, 129.7, 129.5, 124.6, 124.1, 123.5, 67.5, 65.3, 63.8, 60.0, 52.2, 48.8, 46.8, 39.8, 29.9, 25.2; FT-IR (CHCl 3 ) 2924 .8, 2855 .7, 1651 .9 cm 4, 163.7, 149.2, 145.2, 145.1, 144.0, 138.3, 131.3, 130.1, 130.0, 129.0, 128.5, 128.4, 127.4, 127.3, 124.5, 124.2, 123.0, 67.6, 67.5, 59.1, 55.3, 54.8, 51.9, 46.8, 38.8, 33.0, 31.0, 30.4, 28 
